A lthough phosphodiesterase 4 inhibitors and the volatile anesthetic sevoflurane have independent bronchodilator qualities, the combined administration of these agents can potentially exert an additive or synergistic bronchodilator effect. Researchers tested this hypothesis and investigated the common site of this combined relaxation effect in a model of airway hyperresponsiveness with ovalbumin-sensitized guinea pigs. The 138 animals were randomized into 6 groups: sensitized, sevoflurane, rolipram 1.0, roflumilast 1.0, sevoflurane/rolipram 1.0, and sevoflurane/roflumilast 1.0. Total lung resistance in vivo, airway smooth muscle tension in vitro, and intracellular cyclic adenosine monophosphate levels were measured to assess the relaxation effect. Among the 6 sensitized groups, total lung resistance was higher in the order of sensitized > sevoflurane > rolipram1.0 > roflumilast 1.0 > sevoflurane/ rolipram 1.0 > sevoflurane/roflumilast 1.0, with an increase in acetylcholine concentration. Compared with the other 5 groups, the muscle tensions in the sevoflurane/roflumilast 1.0 group were markedly lower at carbacholine doses of 10 −7 , 10 −6 , and 10 −5 M. The cyclic adenosine monophosphate concentrations (means ± SD) in the sevoflurane/rolipram 1.0 (1.61 ± 0.34) and sevoflurane/ roflumilast 1.0 (1.50 ± 0.20) groups were higher than those in the sensitized (0.52 ± 0.15) and sevoflurane (1.12 ± 0.32) groups.The investigators concluded that the combined use of phosphodiesterase 4 inhibitors with the volatile anesthetic sevoflurane had an additive bronchodilator effect in guinea pigs sensitized with ovalbumin. The accompanying increase in cyclic adenosine monophosphate levels in sensitized airway smooth muscle might be a mechanism of this combined relaxation effect.
COMMENTPatients with airway hyperreactivity (eg, chronic obstructive pulmonary disease, asthma) are being recognized increasingly throughout the globe. Many of the volatile anesthetic agents are potent bronchodilators, but there appears to be consensus that sevoflurane irritates the airway least among the volatile agents that include halothane, enflurane, isoflurane, and sevoflurane. 1 Hence, it is not surprising that many authors have recommended the administration of sevoflurane in patients with reactive airway diseases and even in those with status asthmaticus. 2,3 Phosphodiesterase 4 inhibitors and sevoflurane are thought to have independent bronchodilator properties. The current investigation, which was performed on animals with sensitized airways, showed that a new-generation roflumilast and sevoflurane produced additive airway relaxation via an increase in airway smooth muscle cyclic adenosine monophosphate levels. These findings suggest that a combination of these 2 agents might be considered to provide better protection against airway disease when patients with airway hyperreactivity require a general anesthetic. Comment by Kathryn E. McGoldrick, MD, FCAI(Hon) Disclosure: The author declares no conflict of interest.REFERENCES 1. Doi M, Ikeda K. Air...